HighTower Advisors
REGN icon

HighTower Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

HighTower Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-400
Closed -$1.19M – 3625
2022
Q4 		$1.19M Buy
+400
New +$295K ﹤0.01% 1584

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HighTower Advisors's REGN Position: Q1 2026 in Review

HighTower Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 28% in Q1 2026, buying an estimated $9.83M and bringing the position to 58,925 shares worth $45.5M. The position accounts for 0.05% of the portfolio, ranked #380.

HighTower Advisors first reported a position in REGN in Q4 2013 and has held it in 50 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • HighTower Advisors held 58,925 shares of Regeneron Pharmaceuticals worth $45.5M as of Q1 2026.
  • HighTower Advisors bought 12,838 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $9.83M.
  • Regeneron Pharmaceuticals made up 0.05% of HighTower Advisors's portfolio in Q1 2026, its #380 holding.
  • HighTower Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2013 and has held it in 50 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.